Asarina Pharma AB Reaches Full Patient Enrolment in Its Phase Iia Menstrual Migraine (Mm) Study
September 30, 2020 at 04:17 am EDT
Asarina Pharma AB (publ) has reached full patient enrolment in its Phase IIa menstrual migraine (MM) study. 158 women have been recruited as scheduled at seven test centers across Sweden and Finland despite Covid-19 restrictions. Sepranolone, the endogenous compound being tested for MM, is the first therapy to focus exclusively on menstrual migraine. MM affects 50 million women worldwide and is resistant to standard migraine treatments including the new CGRP antibodies. Topline results are expected in Second Quarter 2021.